Analyst Price Target is $43.60
▲ +57.97% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Collegium Pharmaceutical in the last 3 months. The average price target is $43.60, with a high forecast of $50.00 and a low forecast of $36.00. The average price target represents a 57.97% upside from the last price of $27.60.
Current Consensus is
Moderate Buy
The current consensus among 5 contributing investment analysts is to moderate buy stock in Collegium Pharmaceutical. This rating has held steady since July 2024, when it changed from a Hold consensus rating.
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.
Read More
